March 2017 Asbmb Today 1 President’S Message

Total Page:16

File Type:pdf, Size:1020Kb

March 2017 Asbmb Today 1 President’S Message CONTENTS NEWS FEATURES PERSPECTIVES 2 18 31 PRESIDENT’S MESSAGE SOLVING THE FACULTY EDUCATION Biochemists, unite! DIVERSITY PROBLEM Starting the organelle wars 3 24 34 NEWS FROM THE HILL MEET ANNE-CLAUDE GINGRAS DUE DILIGENCE Let’s talk about reproducibility Pixel perfect 28 4 MEET STEVE CARR 36 MEMBER UPDATE OUTREACH 6 18 Eective communication: dream or reality? RETROSPECTIVE 37 6 Susan Lindquist (1949 – 2016) ESSAY 9 ressa C. Stadtman (1920 – 2016) 37 Is biochemistry a tool or a discipline? 38 Working at Manylabs, 12 an open science space NEWS 40 Just like Boyd 12 Cox wins Tabor award for work on extracellular matrix 13 Hidden information in mRNA 42 THE DO-OVER 14 If I could turn back time LIPID NEWS PI-PLC β1 in dierentiation 44 and disease 31 OPEN CHANNELS Bradley Graba Make or break 15 describes how he discovered a new JOURNAL NEWS way to teach cell 37 15 A factory runs riot biology to high- 16 Predicting when blood goes bad school students 17 Targeting cholesterol for ALS treatment using Twitter. 6 42 THE DO-OVER MARCH 2017 ASBMB TODAY 1 PRESIDENT’S MESSAGE THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY Biochemists, unite! OFFICERS COUNCIL MEMBERS By Natalie Ahn Natalie Ahn Squire J. Booker President Victoria J. DeRose Wayne Fairbrother Steven McKnight Karen G. Fleming he American Society of Past President Rachel Green Biological Chemists, Jennifer DuBois Susan Marqusee Jared Rutter Secretary T which later became Celia A. Shier the American Society for Toni M. Antalis Michael Summers Treasurer Biochemistry and Molecu- ASBMB TODAY EDITORIAL lar Biology, was founded EX-OFFICIO MEMBERS ADVISORY BOARD more than 100 years ago. Natalie Ahn Rajini Rao Steven McKnight Chair e founders’ aim was to Co-chairs, 2017 Annual Charles Brenner embrace the biological Meeting Program Past Chair sciences from the chemical Committee Ana Maria Barral point of view and separate Cheryl Bailey Floyd “Ski” Chilton Chair, Education and Henrik Dohlman biochemistry from physiol- Professional Development Peter J. Kennelly ogy as a distinct scientic Committee Beronda Montgomery A. Maureen Rouhi pursuit. Our elds of Daniel Raben Chair, Meetings Committee Melissa Vaught biochemistry and molecular Binks W. Wattenberg Takita Felder Sumter biology dened the molecu- lar and chemical mecha- Chair, Minority Aairs ASBMB TODAY Committee Angela Hopp nisms that govern biological omas Baldwin Executive Editor, processes, fostering one of Chair, Public Outreach [email protected] Committee the most productive areas of Rajendrani Mukhopadhyay Wesley Sundquist Managing Editor, scientic investigation. Chair, Public Aairs [email protected] Today, the ASBMB Advisory Committee John Arnst continues to stand for the Amnon Kohen Science Writer, discovery and understanding Chair, Publications [email protected] Committee Valery Masterson the molecular mechanisms Designer, Lila M. Gierasch of life at deeper levels. We [email protected] tion for discovery across the wide Editor-in-chief, JBC Ciarán Finn stand for education: We provide each spectrum of biological and medical A. L. Burlingame Web Editor, new generation of scientists and edu- sciences? Binks Wattenberg, Enrique Editor, MCP [email protected] cators with mentorship and resources De La Cruz and Dan Raben begin a Allison Frick Edward A. Dennis to teach critical thinking, problem Editor-in-chief, JLR Media Specialist, discussion to answer this question for [email protected] William L. Smith solving and the other skills of great biochemists in their Perspectives essay Barbara Gordon Editor-in-chief, JLR scientists. We are prominent national Executive Director, on page 37. Keeping our community [email protected] advocates: We reach out on behalf of alive enables each of us to ourish. our members and the larger commu- You can help make us even stron- nity of scientists to inform govern- ger. Not a member of the ASBMB? For information on advertising, contact Pharmaceutical mental and nonscientic groups about Please join our community today. Media Inc. at 212-904-0374 or [email protected]. the consequences of policy decisions Already a member? Enlist a colleague on science. We also inform scientists to join too. It’s easy: Go to www. about policies that aect our research asbmb.org/membership/ or email and teaching. And, most importantly, [email protected]. www.asbmb.org/asbmbtoday we foster community by creating a PRINT ISSN 2372-0409 home for people to nd collabora- Articles published in ASBMB Today reect solely tions, share ideas and promote careers. Natalie Ahn the authors’ views and not the ocial positions of ([email protected]) of the the American Society for Biochemistry and Molecular What does it mean to be a bio- Biology or the institutions with which the authors University of Colorado, Boulder, is are aliated. Mentions of products or services are chemist or molecular biologist as our president of the ASBMB. not endorsements. elds increasingly become the founda- 2 ASBMB TODAY MARCH 2017 NEWS FROM THE HILL Let’s talk about reproducibility By Benjamin Corb n 2015, Leonard Freedman, the fact is that we need more data before Societies for Experimental Biology, founder and president of the we can draw rm conclusions. set the issue of reproducibility as the I Global Biological Standards Initia- Researchers at the Center for Open need for scientists to be transparent, tive, and colleagues published a report Science recently began their own careful, diligent about recordkeeping, that claimed $28 billion worth of analysis on reproducibility, specically and mindful of reducing potential biomedical research is irreproducible. in cancer research projects (3). eir pitfalls, such as conrmation bias and e amount accounts for more than preliminary results are complicated. poor study design, while conduct- 50 percent of all preclinical Project researchers are examining 29 ing research. Scientists rightfully feel research grants. papers published in Science, Nature proud of the enormous contribu- is analysis, published in PLOS and Cell since 2012, repeating the tions made by biomedical research, Biology (1), shook scientists and same experiments and asking whether but they can get defensive about science advocates alike. Articles and or not they can reproduce the nd- their work, which can complicate the blog posts critical of the study have ings. One unique aspect of this repro- issue. Moreover, even the denition been published in the 18 months since ducibility eort is its transparency. of what constitutes reproducibility is Freedman’s analysis was published, Unlike previous eorts that have not murky, because science, particularly including by us and others, that were shared which papers they attempted biological science, is complex. Small critical of his study, citing concerns to reproduce, this group is publish- environmental dierences from one over Freedman’s potential conicts of ing their ndings from beginning to lab to another or unclear methodology interest (2). end — the papers they reviewed, the explanations can aect the ability of e inability of scientists to procedures and methods they fol- one researcher to reproduce the reproduce other scientists’ ndings is lowed, and their entire results are all results of another. an issue that the biomedical research available for review and scrutiny. Sean Nevertheless, rather than overreact- enterprise should be concerned about, Morrison, a senior editor of eLife, told ing to criticisms regarding reproduc- especially given that so much of the Nature, “For people keeping score ibility, let’s commit to the goal of research is funded by the federal at home, right now it’s kind of two government, which is to say taxpay- out of three that appear to have been making our scientic work careful, ers. Being good stewards of taxpayer reproduced” (4). scholarly and impactful. If we articu- money must mean conducting sound Conversations about reproducibil- late this goal clearly, then the enter- science. Sound science requires ity can be dierent among scientists prise will be better protected against reproducibility. But is the amount of because the importance of the issue any future criticisms, and perhaps research irreproducibility in the life may vary signicantly across dier- then we’ll show the criticisms to be sciences really so clear-cut that we can ent disciplines. Some eorts, like one irreproducible. chastise an entire community? e led by the Federation of American Benjamin Corb REFERENCES ([email protected]) is director 1. Freedman, L. P., et al. PLOS Biol. 13, e1002165 (2015). of public affairs at the American 2. http://policy.asbmb.org/2015/06/22/research-reproducibility-rises-to-the-top/. Society for Biochemistry and 3. Nosek, B. & Errington, T. eLife 6, e23383 (2017). Molecular Biology. Follow him on Twitter at twitter.com/bwcorb. 4. Baker, M. & Dolgin, E. Nature 541, 269 (2017). Interested in science policy? Follow our blog for news, analysis and commentary on policy issues aecting scientists, research funding and society. Visit policy.asbmb.org. MARCH 2017 ASBMB TODAY 3 MEMBER UPDATE Six ASBMB members named fellows of the National Academy of Inventors Francis Barany of Weill Cornell University, Barbara D. Boyan of Virginia Commonwealth University, Paul L. Modrich of Duke University, Nicholas Muzyczka of the University of Florida, Ronald T. Raines of the University of Wisconsin–Madison and Bruce W. Stillman of Cold Spring Harbor Laboratory have been nominated as 2016 fellows of the National Academy of Inventors. NAI fellows are named inventors on U.S. patents who are nominated by their peers for their outstanding contribu- tions as innovators. Fellows are recognized for having a signicant eect on society through innovations in patents and licensing as well as discovery and technology. ese six members, along with the other 2016 NAI fellows, will be inducted as part of the Sixth Annual Confer- ence of the National Academy of Inventors in April. BARANY BOYAN MODRICH MUZYCZKA RAINES STILLMAN Serio to be dean Hartl and Schulman named program pairs renowned scientists with leading biomedical research at UMass Amherst visiting professors institutions as a means of promoting Tricia R.
Recommended publications
  • Professor Julie Audet<B>
    University of Toronto Faculty, Staff, and Student Awards and Honours Governing Council Meeting October 23, 2008 Faculty & Staff Awards Professor Emeritus Paul Aird of forestry is the winner of the Endangered Species Stewardship Award, presented to him by Donna Cansfield, Ontario minister of natural resources, at a natural History Day event, held May 24 at Bonnechere Provincial Park in Renfrew County. Aird was honoured for his volunteer contributions related to Kirtland’s Warbler over the past 30-plus years, not only raising public awareness for this particular species at risk but for having made an important contribution towards recovery of this globally rare bird in Ontario. Keith Ambachtsheer, director of the Rotman International Centre for Pension Management, is the recipient of the James R. Vertin Award, given by the CFA (chartered financial analyst) Institute to recognize individuals who have produced a body of research notable for its relevance and enduring value to investment professionals. Ambachtsheer received the award July 22 at the 50th Financial Analysts Seminar, a CFA Institute conference hosted by the CFA Society of Chicago. Francesca Andrade of financial services is this year’s winner of U of T Scarborough’s Patrick Phillips Staff Award for outstanding service and commitment by a campus staff member, while Svetlana Mikhaylichenko of physical and environmental sciences is the recipient the D.R. Campbell Merit Award for enhancing the quality of life on campus. Professor Janet Potter of physical and environmental sciences is the winner of the Faculty Teaching Award. The Principal’s Awards were presented in June at an event hosted by Principal Franco Vaccarino.
    [Show full text]
  • 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
    Case 2:16-cv-02373-SPL Document 1 Filed 07/15/16 Page 1 of 36 1 Mark D. Samson Ron Kilgard 2 KELLER ROHRBACK L.L.P. 3 3101 North Central Ave., Suite 1400 Phoenix, AZ 85012 4 Phone: (602) 248-0088, Fax (602) 248-2822 5 [email protected] [email protected] 6 Lynn Lincoln Sarko (pro hac vice application forthcoming) 7 Gretchen Freeman Cappio (pro hac vice application forthcoming) 8 T. David Copley 1201 Third Avenue, Suite 3200 9 KELLER ROHRBACK L.L.P. 10 Seattle, WA 98101-3052 (206) 623-1900, Fax (206) 623-3384 11 [email protected] [email protected] 12 [email protected] 13 Attorneys for Plaintiffs 14 15 UNITED STATES DISTRICT COURT DISTRICT OF ARIZONA 16 R.C., individually and on behalf of all others 17 similarly situated, No. 18 Plaintiff, 19 CLASS ACTION COMPLAINT v. 20 JURY TRIAL DEMANDED THERANOS, INC., a California 21 Corporation, and WALGREENS BOOTS 22 ALLIANCE, INC., a Delaware Corporation, 23 Defendants. 24 25 26 27 COMPLAINT 28 1 Case 2:16-cv-02373-SPL Document 1 Filed 07/15/16 Page 2 of 36 1 I. INTRODUCTION 2 1. Blood tests are a critical component of a patient’s healthcare. Patients, as well as 3 their doctors, rely on blood tests to detect conditions and use those results to help determine which 4 course of treatment is or isn’t needed. Inaccurate blood test results can contribute to serious 5 6 conditions going undetected, to treatable conditions growing worse unnoticed, to patients forgoing 7 medications they should take or taking medications they shouldn’t.
    [Show full text]
  • Enabling Comprehensive Assessments of Drug–Drug Interaction Risks
    R&D Solutions for PHARMA & LIFE SCIENCES PHARMACOVIGILANCE Enabling Comprehensive Assessments of Drug–Drug Interaction Risks Summary Dr. Kevin Lustig, President and CEO of The Assay Depot, Inc., and Dr. Maria Thompson, Principal Consultant, look at the dynamics of drug metabolizing enzymes and transporters and how an understanding of this critical aspect of biology enables assessments of drug–drug interaction risks. In addition, they comment on PharmaPendium®, which includes the DMPK solution with its DDI Risk Calculator, as an important tool in making these assessments successfully. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. Abstract Understanding the dynamics of drug metabolizing enzymes and transporters (METs) is critical to successful drug development. MET behavior can significantly impact drug safety. Many factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and mediate drug interactions. Evaluation of drug interaction profiles required detailed in vitro and in vivo studies along with predictive modeling. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. This MET data and the ability to predict drug–drug interactions (DDIs) are incredibly valuable for optimized research workflows and accelerated drug development. They enable intelligent, in silico drug design and provide scientists with comprehensive knowledge about drug metabolism, significantly reducing the need for costly and time-consuming lab work and animal models and informing critical decisions on clinical trial design. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy and safety, both of which are intimately linked to drug metabolism.
    [Show full text]
  • DRUG DISCOVERY SUMMIT: Enabling Early Stage Drug Discovery and Venture Creation
    PRESENT: DRUG DISCOVERY SUMMIT: Enabling Early Stage Drug Discovery and Venture Creation Event Program JLABS@Toronto Tuesday June 11, 2019 MaRS Centre, West Tower 1:00 – 6:00 PM 661 University Avenue, Suite 1300 Toronto, ON, Canada M5G 0B7 POWERED BY: WELCOME MaRS Innovation and our partner Evotec SE are pleased to welcome you to our inaugural LAB150 Drug Discovery Summit. We would like to thank Allan Miranda and the JLABS team for hosting us here today in this spectacular facility! It has been 18 months since we launched LAB150, a program designed to enable translation of academic discoveries into medicines from MaRS Innovation (MI) Members. With five projects approved and funded and one project graduated from the program and negotiating follow-on investment, we are off to an incredible start! The LAB150 program, paired with MI’s venture creation and investment model, provides a leading platform for life sciences venture creation and growth in Canada. Over the last decade, MI has created over 50 companies that have attracted and retained seasoned management, created over 400 STEM jobs and raised over $350M in direct third-party capital. With LAB150, we look forward to building on this success in the coming decade and beyond. Today you will hear from entrepreneurs and scientists regarding their experiences with the LAB150 program. In addition, we are pleased to be joined by scientific experts from Evotec who will share emerging trends in the drug discovery space. Last but not least, early stage investors will share their tips and tricks for securing capital for building therapeutic ventures in Canada.
    [Show full text]
  • July Updates: People and Places
    career news July Updates: People and Places Skills and knowledge transfer alpha-synuclein A53T knock-in model; and commented in a press release, The NC3Rs has awarded a total of £219,339 the continued development of a pre-clinical “The partnership enables Scientist.com this year to three researchers through the model to test LRRk2 kinase inhibitors as a users to easily access innovative rodent 2018 NC3Rs Skills and Knowledge Transfer treatment for PD. models generated with the latest funding competition, designed to promote CRISPR technology.” the post-development uptake of new 3Rs Easi editing approaches. Laura Scullion Hall from The University of Nebraska recently Understanding aging fat the University of Stirling will partner with licensed its Easi-CRISPR gene editing Kristy Townsend, a neurobiologist at the pharmaceutical company GSK to develop technology to Taconic Biosciences. The University of Maine in Orono, has received an online learning platform for research dog CRISPR variant, developed by Masato a three-year $750,000 grant from the handling and welfare. Jonathan Brown from Ohtsuka at the University of Tokyo and American Heart Association to study links the University of Exeter will use the award Channabasavaiah Gurumurthy at the between fat tissue and cardiovascular and to apply the TaiNI wireless EEG recording University of Nebraska, enables the site- metabolic diseases in aging mouse models. technology he developed with scientists at specific insertion of large sequences Recent work from her lab has revealed Eli Lilly through the NC3Rs CRACK IT of DNA, an improvement to previous evidence of “adipose neuropathy”—fat Challenge to dementia research in mice.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • Understanding Key Determinants of Drug Activity
    CASE STUDY Dr. Kevin Lustig, President and CEO, The Assay Depot, Inc. Greater San Diego Area Understanding Key Determinants of Drug Activity SUMMARY This article highlights the increasing role that drug metabolism and transport proteins have in the drug approval process. CASE STUDY: The Assay Depot, Inc. The dynamics of drug metabolizing enzymes and transporters is critical to the development of personalized medicine strategies. Abstract / Summary The dynamics of drug metabolizing enzymes and transporters is critical to the develop- ment of personalized medicine strategies. A multitude of factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and medi- ate drug interactions. Evaluation of drug interaction profiles is a critical step in drug development and necessitates detailed in vitro and in vivo studies along with predictive modeling. PharmaPendium® via its Metabolizing Enzymes and Transporters Module provides unprecedented depth of data on drug metabolizing enzymes and transporters and offers a unique platform for modeling advanced drug interactions. This Module will prove to be a valuable resource capable of improving workflows and accelerating devel- opment by enabling intelligent, in silico drug design. By providing scientists with all of the available knowledge about drug metabolism, we can significantly reduce the need for costly and time-consuming lab work and animal models. Requiring these only to answer the true unknowns where no one else has gone before. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy Dr. Kevin Lustig, Author and safety, both of which are intimately linked to drug metabolism. Hence knowledge President & CEO, The Assay Depot Inc.
    [Show full text]
  • Theranos Phenomenon – Part 5: Theranos’ Presentation at the American Association for Clinical Chemistry Annual Conference 2016
    Clin Chem Lab Med 2016; 54(10): e313–e314 Letter to the Editor Eleftherios P. Diamandis* and Mario Plebani Theranos phenomenon – Part 5: Theranos’ presentation at the American Association for Clinical Chemistry Annual Conference 2016 DOI 10.1515/cclm-2016-0737 Master, two highly recognized and respected clinical Accepted for publication August 18, 2016; previously published chemists, who did a good job in asking pertinent ques- online August 30, 2016 tions to Ms. Holmes and her associates. In this respect, AACC lived up to the expectations of high standards and Keywords: diagnostics; new technologies. impartiality for this presentation. Holmes presented to a large and curious, if not To the Editor, hostile, audience. She avoided talking about Theranos’ past and the difficulties of her company [1–7]. She also The widely anticipated presentation of Theranos at the made it clear that her presentation would focus on the Annual Conference of the American Association for future, not the past, and she distanced herself from the Clinical Chemistry (AACC) was finally given on Monday, previous “Edison” instrument and introduced a new August 1st, 2016 at the Philadelphia Convention Center. analyzer named “MiniLab”. In the first part of her pres- This journal has followed the Theranos story closely over entation, Ms. Holmes described the engineering behind the last 2 years and provided frequent updates [1–4]. Eliza- the MiniLab and explained that it is a compact desktop beth Holmes, the Chief Executive of Theranos, presented device that houses a mini spectrophotometer, a mini- to an audience of over 2500 clinical chemists and other luminometer, and mini-flow-cytometer and a mini-PCR laboratory scientists, as well as to an impressive number machine, along with a centrifuge.
    [Show full text]
  • Strategic Outsourcing of Pharmaceutical R&D
    CHEMSITRY TODAY Vol 31(4) P. 14-17 / CROS/CMOS Strategic outsourcing of pharmaceutical R&D - Bringing pharma and drug discovery into the information age KEVIN LUSTIG Assay Depot, Inc Corresponding Author KEVIN LUSTIG: Assay Depot, Inc, email: [email protected] KEYWORDS: Outsourcing; innovation; lean; drug; research; discovery ABSTRACT: The centralized model of pharmaceutical development that was used successfully through most of the last century is no longer a good fit. Advances in modern molecular research have changed the playing field to such an extent that the old model is no longer viable. If drug companies can solve the problems of pre-clinical development and deliver a steady stream of new, high- quality compounds to the clinic, then the challenges currently facing pharma will become a thing of the past. The single most likely route to success is through the application of strategic outsourcing, which if done correctly, can dramatically reduce research costs while simultaneously improving research quality. Utilizing new online tools such as research exchanges, a “lean” pharmaceutical company can find and manage a large number of specialist scientific service providers and experts that can bring exactly the right skill set to bear at the right time in the project cycle. INTRODUCTION Few would argue that the Pharmaceutical Industry has been languishing in the doldrums now for well over a decade. Pharmaceutical companies are having to face three major issues involving drug approvals, development costs and patents expirations. Any of these alone would prove a tough nut to crack, but the fact that they are all converging at the same time is creating a perfect storm! • A paucity of new drug approvals: 2010 was one of the worst years on record, with the European Medicines Agency showing only 41 finalized applications, compared to 125 in 2009.
    [Show full text]
  • Marketplaces for Sharing Scientific Data and Outsourcing R&D Activities: the Case Study of the Pharmaceutical, Life Sciences and Bio-Medical Industries
    MARKETPLACES FOR SHARING SCIENTIFIC DATA AND OUTSOURCING R&D ACTIVITIES: THE CASE STUDY OF THE PHARMACEUTICAL, LIFE SCIENCES AND BIO-MEDICAL INDUSTRIES In the present document, we aim to review the main protagonist companies in the field of the outsourcing of biomedical R&D research and in the sharing of scientific data and contract- research consultancy services. This effort is part of a longer-term objective aimed at assessing the current state of the R&D outsourcing market via “marketplace” type of websites, in order to estimate the existing potential competition to the core areas of interest of the VIMMP project. Even though, under the current state of affairs, no direct competitors of VIMMP presently exist (within the restricted field of materials modelling coupled with marketplace and data/software sharing type of functionalities), marketplace websites active in other branches of science and technology can still provide invaluable insight in demonstrating how such R&D commercial operations can be implemented and exploited successfully and profitably. 1. General Introduction to R&D Outsourcing Services Advances in science, technology, and engineering impact our daily lives and fuel economic growth and prosperity. Investment in innovation and R&D drives these advances, and it is the hi-tech companies and their respective industries that dominate global R&D spending. Hardware/software, electronics, automotive, aerospace and defense, telecommunications, and pharmaceutical/biotech all feature as the highest R&D spending industries. The pharmaceutical/biotech industry has the highest levels of R&D outsourcing across hi-tech industries, with its outsourcing growth rate outstripping internal investments. Some large pharmaceutical companies suggest that 40% or more of their R&D spend will be outsourced in the near future, and that clinical operations functions will eventually be outsourced entirely.
    [Show full text]
  • Motility of Acta Protein-Coated Microspheres Driven by Actin Polymerization
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 4908–4913, April 1999 Biophysics Motility of ActA protein-coated microspheres driven by actin polymerization LISA A. CAMERON*, MATTHEW J. FOOTER†,ALEXANDER VAN OUDENAARDEN‡, AND JULIE A. THERIOT†§¶ *Department of Biological Sciences, Stanford University, Stanford, CA 94305-5020; †Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305-5307; ‡Department of Chemistry, Stanford University, Stanford, CA 94305-5080; and §Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305-5124 Communicated by James A. Spudich, Stanford University School of Medicine, Stanford, CA, March 1, 1999 (received for review January 12, 1999) ABSTRACT Actin polymerization is required for the gen- moving endosomes (J. Heuser, personal communication) and eration of motile force at the leading edge of both lamellipodia phospholipid vesicles (11). Although much is understood and filopodia and also at the surface of motile intracellular about the biochemical mechanisms of catalyzing actin filament bacterial pathogens such as Listeria monocytogenes. Local polymerization in several of these systems (12–14), relatively catalysis of actin filament polymerization is accomplished in little is known about how this local surface catalysis results in L. monocytogenes by the bacterial protein ActA. Polystyrene comet tail formation, force generation, and motility. It is beads coated with purified ActA protein can undergo direc- striking that a variety of biochemical mechanisms for cata- tional movement in an actin-rich cytoplasmic extract. Thus, lyzing local actin polymerization on the surface of a small the actin polymerization-based motility generated by ActA can object (bacterium, virus, or membrane vesicle) all result in the be used to move nonbiological cargo, as has been demon- same type of actin self-organization and movement.
    [Show full text]
  • Collaborative Drug Discovery's 10 Anniversary Community Meeting
    Collaborative Drug Discovery’s 10th Anniversary Community Meeting April 4th, 2014 8am-6pm UCSF Mission Bay Conference Center 1675 Owens St. San Francisco, CA 94158 Please use this Twitter hashtag for the event: #CDDx14 Agenda 7:45 Registration - refreshments in Foyer and Exhibition room 8:15 Opening Remarks - with UCSF Host, Stephanie Robertson and CDD CEO, Barry Bunin Collaborative Workflow: Basic and Advanced Use Cases of CDD Vault 8:20 Charlie Weatherall (CDD) & Anna Spektor (CDD) 9:10 Morning Sessions - moderated by Sylvia Ernst (CDD) The Rockefeller University Compound Screening Library 9:15 J. Fraser Glickman (Rockefeller University) Recent Progress in De-Orphanization of Nuclear Receptors 9:40 Ruo Steensma (Orphagen Pharmaceuticals) 10:05 Morning Break - located in the Foyer and Exhibition room Large small molecules in a Small large molecule world 10:35 Leanna Staben (Genentech) Linking the Molecular Structure of Medicines to their Biological Effects 11:00 Bob Volkmann (Systamedic & Mnemosyne Pharmaceuticals) Panel: Externalized Research - What Makes a Good Partnership? Wisdom from Experts 11:25 Who've "Been There - Done That," moderated by Sylvia Ernst (CDD) 11:50 Lunch - boxed lunches in the Foyer and Exhibition room Optional: “What if CDD had...” provide feedback to our product team (12:35) Kellan Gregory (CDD) 10 Years Evolving Our Collaborative Drug Discovery Vaults 1:05 Barry Bunin (CDD) CDD Vault: Noteworthy recent enhancements and a preview of things to come 1:30 David Blondeau (CDD) & Kellan Gregory (CDD) 2:20 Afternoon sessions - moderated Christopher Lipinski The Tuberculosis Drug Accelerator: A New Paradigm For Drug Discovery 2:25 Jerry Shipps (Tuberculosis Drug Accelerator) The role of NIAID in the development of therapeutics for Infectious Diseases 2:50 Martin John Rogers (NIAID) 3:15 Afternoon Break - located in the Foyer and Exhibition Room Targeting the Immunoproteasome 3:40 Dustin L.
    [Show full text]